Alent News - ALNT

Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device

GENEVA, Switzerland, January 30 /PRNewswire-FirstCall/ -- - easypod(R) Was Designed to Improve Ease of Usage, Reliability and Convenience Merck...

Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis

ONWARD Phase II Trial Will Assess Therapeutic Benefit of Oral Cladribine Added-on to New Formulation of Rebif(R) in Multiple Sclerosis Patients...

Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria

Phenoptin Significantly Increases Phenylalanine Tolerance in BH4-Responsive Patients; All Pre-Specified Endpoints Met GENEVA, Switzerland...

Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine

Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis GENEVA, Switzerland, January 16...

Merck Serono is Launched

Top Management Appointed GENEVA, Switzerland, January 8 /PRNewswire-FirstCall/ -- Following the successful closing of the Share Purchase...

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

SEATTLE, Washington and GENEVA, Switzerland, December 20 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (NASDAQ:ZGEN) and Serono (virt-x: SEO and...

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono

GENEVA, Switzerland, December 18 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) has today been informed that Merck KGaA of...

Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multip

First Trial Assessing Therapeutic Benefit of Two Different Dosage Regimens of Disease Modifying Therapy in People With First Clinical Symptoms...

One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immu

Data Presented at 22nd ECTRIMS Congress in Madrid MADRID, Spain, September 28 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Alent (ALNT)

Professional-Grade Tools, for Individual Investors.

ALNT News

Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device

Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis

Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria

Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine

Merck Serono is Launched

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono

Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multip

ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus

Serono Delivers Strong Adjusted* Net Income of $183.5m in Third Quarter 2006

Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide

Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer

One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immu

ALNT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Alent (ALNT) News

Alent (ALNT)

Professional-Grade Tools, for Individual Investors.

ALNT News

Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device

Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis

Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria

Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine

Merck Serono is Launched

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono

Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multip

ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus

Serono Delivers Strong Adjusted* Net Income of $183.5m in Third Quarter 2006

Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide

Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer

One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immu

ALNT Discussion

Your Recent History